Edwards Lifesciences Q3 FY24: where the revenue came from and where it went
The whole income statement of Edwards Lifesciences for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2024
- Reported
- Nov 6, 2024
Revenue$1.35B
+9% year over year
Gross profit$1.09B
81% margin
Operating profit$0.35B
26% margin
Net profit$3.07B
227% margin
Net profit is larger than what operations earned, because the statement adds $2.76B below it, under Other income, net. A margin above a hundred per cent means the same thing.
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 1.35 | 100% | +9% |
| Aortic valve replacement | 1.02 | 75% | +6% |
| Surgical heart valve therapy | 0.24 | 18% | +4% |
| Transcatheter mitral | 0.09 | 7% | +74% |
| Cost of revenue | −0.26 | 19% | |
| Gross profit | 1.09 | 81% margin | +1pp |
| R&D | −0.25 | 19% | −1pp |
| SG&A | −0.42 | 31% | +0pp |
| Other | −0.07 | 5% | +0pp |
| Operating profit | 0.35 | 26% margin | −4pp |
| Other income, net | 2.76 | ||
| Tax | −0.04 | ||
| Net profit | 3.07 | 227% margin | +196pp |
154 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest